20 June 2013
Keywords: uk, nice, rejects, erbitux, advanced, crc, german-swiss
Article | 29 January 2007
German-Swiss drugmaker Merck Serono says that the National Institute for Health and Clinical Excellence (NICE), the UK advisory body responsible
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 January 2007
15 January 2007
19 June 2013
© 2013 thepharmaletter.com